pharma · Acute Myeloid Leukemia · Acute Leukemia · ATNM
Actinium Pharmaceuticals
Actinium Pharmaceuticals clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- New York, USA
- Founded
- 2000
- Employees
- 58
- Programs
- 8
- Drugs
- 4
- Patents
- 20
Actinium Pharmaceuticals projects
8 ClinicalTrials.gov programs sponsored by Actinium Pharmaceuticals.
Actinium Pharmaceuticals has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
131I-apamistamab
Actinium Pharmaceuticals
Acute Leukemia
1 trial -
Iomab-B
Actinium Pharmaceuticals
Acute Myeloid Leukemia
1 trial -
Cytarabine (Phase 1 only)
Actinium Pharmaceuticals
AML
1 trial -
Iomab-B
Actinium Pharmaceuticals
Non Hodgkin Lymphoma
1 trial -
Lintuzumab-Ac225
Actinium Pharmaceuticals
Acute Myeloid Leukemia
2 trials -
131I-apamistmab
Actinium Pharmaceuticals
Sickling Disorder Due to Hemoglobin S
1 trial -
ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195
Actinium Pharmaceuticals
Leukemia
1 trial -
Lintuzumab AC 225
Actinium Pharmaceuticals
Refractory Multiple Myeloma
1 trial
Frequently asked questions
How many clinical projects does Actinium Pharmaceuticals have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.